Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
JUPITER, Fla., Feb. 22, 2011 /PRNewswire/ — Dyadic International, Inc. (“Dyadic”) (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has launched FibreZymeÃ‚® G200, a next generation, high performance enzyme designed to improve paper quality and improve the economics of various pulp and paper manufacturing processes.
Brian Murdoch, Dyadic’s Senior Director Sales & Technical Development stated, “FibreZymeÃ‚® G200 is a great addition to our product portfolio and provides further evidence of the value-adding capabilities of Dyadic’s C1 platform technology. FibreZymeÃ‚® G200 operates under wide pH and temperature ranges allowing for seamless integration into most pulp and paper manufacturing processes.”
Specific attributes of FibreZymeÃ‚® G200 include the following:
- Reduces fiber raw material costs and petroleum-derived chemical usages
- Reduces pulp refining energy requirements
- Increases paper machine production rates and efficiencies
- Improves softness in tissue production
- Enhances pulp drainage rates and reduces paper drying demand
- Enhances and restores fiber strength and increases inter-fiber bonding through fibrillation
New Production Platform
FibreZymeÃ‚® G200 is produced using a new variant of Dyadic’s patented and proprietary C1 platform technology which Dyadic refers to as the “white strain.” Developed through sustained research efforts at Dyadic Netherlands, the white strain produces significantly less background proteins. These changes allow for more efficient and economical industrial scale production of highly targeted enzymes and proteins at greater purity levels.
Richard Jundzil, Dyadic’s Vice President Operations stated, “FibreZymeÃ‚® G200 represents the first product commercialized using the new C1 white strain. We now have in place all the molecular tools, scale-up experience and production processes necessary to support additional timely market introductions of new enzymes identified from the C1 and other genomes. Dyadic intends to utilize the white strain production platform to create a sustainable and more diverse product portfolio. We also intend to express new enzyme and protein targets with our collaborative partners in a variety of industries.”
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Please visit Dyadic’s website at www.dyadic.com and Dyadic Netherland’s website at www.dyadic.nl.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
For more information about FibreZymeÃ‚® G200, please visit www.FibreZyme.com.
SOURCE Dyadic International, Inc.